Skip to main content

Cellectis S.A.

corporate_fare Company Profile

Cellectis S.A.

CLLS·NASDAQ·Life Sciences·CIK 0001627281

Cellectis S.A. is a clinical-stage biotechnology company that develops gene-editing products. The company focuses on allogeneic chimeric antigen receptor T-cells (CAR T-cells) for immuno-oncology and gene therapy product candidates for other therapeutic areas. Its product pipeline includes BALLI-01, which is being developed to assess the safety, expansion, persistence, and clinical activities of lasme-cel in patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). Another product, NatHaLi-01, is designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). Cellectis S.A. also develops ALPHA3, which targets Large B-Cell Lymphoma (LBCL), and TRAVERSE, intended for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). Additionally, the company is developing a product for the treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A. (NASDAQ:CLLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for CLLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CLLS spans 6-K, 20-F.

Recent high-impact activity:

  • Cellectis Posts $101.1M Nine-Month Loss, Books $26.8M Impairment on Pivot
  • Cellectis Pivots to In Vivo Gene Editing, Exits CAR-T Programs
  • Cellectis Q2 2026: Cash Runway into Q4 2027, Lasme-cel Pivotal Data Readout Expected Q4 2026
  • Shareholders Approve Broad Dilutive Capital Raise Authorizations and ATM Program
  • Cellectis Reports Strong Phase 1 Data for Lasme-cel (100% ORR) and Promising Eti-cel Results at EHA

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$72.95M
Net Income
-$67.59M
Diluted EPS
-$0.67
Op. Cash Flow
-$39.4M
Free Cash Flow
-$41.76M
Gross Profit
$72.95M
Operating Income
-$33.08M
Cash & Equivalents
$61.53M
Debt / Equity
0.00×
Net Margin
-92.7%
Shares Outstanding
100.34M sh
Source: 20-F · filed 2026-03-19 · accession 0001193125-26-116428

Short Interest & Short Volume

2.63 days to cover

FINRA reported short interest of 333,012 shares in CLLS as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 2.6 days to cover at its recent average daily volume. On November 20, 2026, 43.0% of CLLS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)333,012 shares as of October 30, 2026
Change vs prior period▲ 3.9%
Days to cover2.63 at avg daily volume of 126,736
Daily short volume (FINRA facilities)43.0% of 27,968 shares on November 20, 2026
5-day average short volume27.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CLLS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.

ATM program

Broad Dilutive Capital Raise Authority Granted · At-The-Market (ATM) Program Authorized

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

CLLS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with C →
$0.9209
52-week range · as of 2026-11-12 $0.8808 – $5.45
Market cap
$72.16M
Volume
52.6K (0.6× avg)
3-mo avg 90.5K
Live data · 2026-11-21 22:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CLLS - Latest Insights

CLLS
Nov 12, 2026, 5:00 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $0.9209 info
Change: -$0.4091 (-31%) info
Market Cap: $72.163M info
CLLS
Sep 14, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $0.9209 info
Change: -$1.18 (-56%) info
Market Cap: $72.163M info
CLLS
Aug 06, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $0.9209 info
Change: -$1.77 (-66%) info
Market Cap: $72.163M info
CLLS
Jun 25, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $0.9209 info
Change: -$1.97 (-68%) info
Market Cap: $72.163M info
CLLS
Jun 11, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.18
Real-time Price: $0.9209 info
Change: -$2.26 (-71%) info
Market Cap: $72.163M info
CLLS
Jun 09, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.33
Real-time Price: $0.9209 info
Change: -$2.41 (-72%) info
Market Cap: $72.163M info
CLLS
Jun 09, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.33
Real-time Price: $0.9209 info
Change: -$2.41 (-72%) info
Market Cap: $72.163M info
CLLS
May 20, 2026, 6:52 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.66
Real-time Price: $0.9209 info
Change: -$2.74 (-75%) info
Market Cap: $72.163M info
CLLS
May 12, 2026, 9:35 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $0.9209 info
Change: -$2.97 (-76%) info
Market Cap: $72.163M info
CLLS
May 11, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $0.9209 info
Change: -$3.06 (-77%) info
Market Cap: $72.163M info
CLLS
May 11, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $0.9209 info
Change: -$3.06 (-77%) info
Market Cap: $72.163M info
CLLS
May 11, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $0.9209 info
Change: -$3.06 (-77%) info
Market Cap: $72.163M info
CLLS
Apr 27, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $0.9209 info
Change: -$3.09 (-77%) info
Market Cap: $72.163M info
CLLS
Apr 13, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.36
Real-time Price: $0.9209 info
Change: -$3.44 (-79%) info
Market Cap: $72.163M info
CLLS
Mar 19, 2026, 7:52 PM EDT
Filing Type: 20-F
Importance Score:
7
Price at Filing: $3.55
Real-time Price: $0.9209 info
Change: -$2.63 (-74%) info
Market Cap: $72.163M info
CLLS
Mar 19, 2026, 7:21 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.54
Real-time Price: $0.9209 info
Change: -$2.62 (-74%) info
Market Cap: $72.163M info
CLLS
Jan 08, 2026, 4:35 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.48
Real-time Price: $0.9209 info
Change: -$3.56 (-79%) info
Market Cap: $72.163M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets